Research Repository

Engineered repressors are potent inhibitors of androgen receptor activity

Brooke, GN and Powell, SM and Lavery, DN and Waxman, J and Buluwela, L and Ali, S and Bevan, CL (2014) 'Engineered repressors are potent inhibitors of androgen receptor activity.' Oncotarget, 5 (4). 959 - 969. ISSN 1949-2553

1360-17178-3-PB.pdf - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview


Prostate cancer growth is dependent upon the Androgen Receptor (AR) pathway, hence therapies for this disease often target this signalling axis. Such therapies are successful in the majority of patients but invariably fail after a median of 2 years and tumours progress to a castrate resistant stage (CRPC). Much evidence exists to suggest that the AR remains key to CRPC growth and hence remains a valid therapeutic target. Here we describe a novel method to inhibit AR activity, consisting of an interaction motif, that binds to the AR ligand-binding domain, fused to repression domains. These 'engineered repressors' are potent inhibitors of AR activity and prostate cancer cell growth and importantly inhibit the AR under circumstances in which conventional therapies would be predicted to fail, such as AR mutation and altered cofactor levels.

Item Type: Article
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Science and Health > Life Sciences, School of
Depositing User: Jim Jamieson
Date Deposited: 17 Jun 2014 15:39
Last Modified: 19 Aug 2019 17:16

Actions (login required)

View Item View Item